Using a sensitive immunoradiometric assay, serum concentrations of thyrotrophin (TSH) were measured both basally and after intravenous thyrotrophin releasing hormone (TRH) in two groups of patients with destructive pituitary lesions. Group A patients, who had more extensive pituitary hormone deficiencies and biochemical evidence of hypothyroidism at the time of study, had significantly lower mean serum TSH concentrations than the group B patients who were biochemically euthyroid. Basal TSII was below the lowest value seen in a control group of normal subjects in 5 of the 8 group A patients. In all patients TSII increased significantly after injection of TRH; the peak values being significantly correlated with the basal. In contrast to recent studies, which have emphasised other mechanisms in the production of secondary hypothyroidism, our data suggest that inadequate production of immunoassayable TSII is a common cause of secondary hypothyroidism in patients with destructive pituitary disease. Little, if any, additional clinical information is to be gained by measurement of TSII after TRH stimulation in this circumstance.
Using a sensitive immunoradiometric assay, serum concentrations of thyrotrophin (TSH) were measured both basally and after intravenous thyrotrophin releasing hormone (TRH) in two groups of patients with destructive pituitary lesions. Group A patients, who had more extensive pituitary hormone deficiencies and biochemical evidence of hypothyroidism at the time of study, had significantly lower mean serum TSH concentrations than the group B patients who were biochemically euthyroid. Basal TSII was below the lowest value seen in a control group of normal subjects in 5 of the 8 group A patients. In all patients TSII increased significantly after injection of TRH; the peak values being significantly correlated with the basal. In contrast to recent studies, which have emphasised other mechanisms in the production of secondary hypothyroidism, our data suggest that inadequate production of immunoassayable TSII is a common cause of secondary hypothyroidism in patients with destructive pituitary disease. Little, if any, additional clinical information is to be gained by measurement of TSII after TRH stimulation in this circumstance.
Recent studies have emphasised that serum immunoreactive thyrotrophin (TSH) concentrations are frequently normal or raised in patients with secondary hypothyroidism. I. 2 It has therefore been presumed that in the majority of such patients hypothyroidism does not result from deficient secretion of immunoassayable TSH. We have examined this question using a sensitive immunoradiometric asssay (IRMA) for TSH which can measure very low serum concentrations with precision.'
Materials and methods

PATIENTS
Twenty patients (13 men, 7 women) aged 17-72 years (mean 47) with destructive lesions of the pituitary gland were studied. All but three of Correspondence: Joan Butler. Principal Biochemist, Department of Chemical Pathology, King's College Hospital, London SE5 9RS. UK. 620 the patients had been treated by radiotherapy and/or pituitary surgery and ten were receiving replacement therapy with hydrocortisone and/ or testosterone andlor desmopressin. Hydrocortisone treatment (eight patients) was prescribed if the 09.00 h plasma cortisol was less than 200 nmoIlL or the peak plasma cortisol after insulin-induced hypoglycaemia did not reach 500 nmol/L. Testosterone treatment (one male patient) was prescribed, if the total serum testosterone was below 10 nmol/L and there were symptoms of hypogonadism. Desmoprcssin treatment (two patients) was prescribed if there was evidence of partial or complete diabetes insipidus on an 8 h water deprivation test. None was on thyroxine replacement. Five patients were being treated with brumocriptinc because of persistent hypcrprolactinaernia (> 1000 mUlL), but only one patient had a serum prolactin concentration in excess of 1000 mUlL at the time of study.
Our criterion for diagnosing hypothyroidism (which is necessarily arbitrary) was a low serum free thyroxine (IT 4 ) concentration. On this basis, eight of the patients (Group A) were hypothyroid (IT 4<9 pmol/L) and twelve (group B) were euthyroid (Table I) . None of the patients was severely ill, although five of the eight group A patients (but none of the group B) had symptoms suggestive of hypothyroidism. In all group A cases the presence of primary thyroid failure was excluded as far as possible by the absence of goitre and of thyroid cytoplasmic antibodies in the serum. In five of these cases thyroid function was known to have been biochemically normal before surgery or radiotherapy had been undertaken. Serum TSH, IT 4 , total thyroxine (tT 4 ) and total triiodothyronine (tT J ) were measured both in the patients and in a control group (Group C) of fifteen normal subjects (seven men, eight women) aged 18-50 (mean 30) years who had no history of thyroid dysfunction.
METHODS
Serum TSH was measured basally and, in group
A and B patients, at 20 min and 60 min after the intravenous injection of 200~lg synthetic thyrotrophin releasing hormone (TRII, Roche Products. UK). Sampling was undertaken in the late morning or early afternoon on all subjects.
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Serum TSH concentrations were measured by an IRMA method using two monoclonal anti-TSH antibodies ('Sucrosep', Boots Celltech Diagnostics Limited, UK). The limit of detection was O·()S to 0,) mUlL. The working range with an intra-assay coefficient of variation of <\()% was ()·3 to 200 mUlL. Inter-assay variation was 8·6% at ()'6 mUlL and 4·8% at 5·5 mUlL. The normal range is ().4-6.() mUlL. Serum IT 4 concentrations were measured by radioimmunoassay employing a labelled analogue (Amerlex-M, Amersham International, UK). The inter-assay coefficient of variation was \0·2% at 3·6 pmol/L and 3·8% at 13·2 pmol/L. The manufacturer's normal range is 9-24 pmol/L. Serum tT 4 concentrations were measured by radioimmunoassay (Amerlex-M, Arnersham International, UK). The manufacturer's normal range is 60-165 nmol/L, Serum tT J concentrations were measured by an 'inhouse' double antibody radioimmunoassay. The normal range is 1·2-3·1 nmol/L, All samples were measured in duplicate.
Statistical analysis
Serum TSH, IT 4 , tT 4 Since serum TSH values had a markedly skewed distribution the results have been 10glO transformed before analysis. The results are given as the antilogj., and expressed as the mean (±SEM). Frequency distributions were compared using Fisher's exact probability test or the ' 1. 2 test (with Yates' correction) as appropriate.
Results
TSH was detectable in the serum of all but one of the subjects studied. The basal levels ranged from undetectable to 1·2 mUlL in group A, from 0·4 to 3·9 mUlL in group B and from 0·65 to 3·3 mUlL in group C. Mean values for TSH were significantly lower in group A than in groups Band C ( Table 2 ). However three group A patients had basal serum TSH concentrations greater than the lowest value seen in group C. Basal serum TSH concentrations were below the detection limit for conventional radioimmunoassays (l mUlL) in 75% of group A, 25% of group Band 7% of group C. Serum ff 4 concentrations were of course -significantly lower in group A patients than the others. There was a small but statistically significant difference in mean ff 4 levels be- Bosol TSH (mull)
Relations between the basal serum T5H and the peak value obtained after intravenous TRH (irrespective of whether the peak occurred at 20 or 00 min). A striking relationship exists (r=()'!l5, P<O·OOI). Group A patients are indicated by closed circles and Group B by the open. The patient witb an undetectable basal TSH level has been ascribed the value O·J mUlL (the detection limit of the assay). Note the logarithmic co-ordinates.
tween groups Band C. Serum tT.J concentrations were also markedly reduced in group A patients in comparison to groups Band C. but mean values also differed significantly between the latter. Similar findings were noted for serum tT 3 concentrations ( Table 2 , Fig. I) .
In response to TRII, serum TSH concentrations increased in all patients (p«).()(J\). In seven of eight group A patients and seven of 12 group B patients the peak serum TSH concentration was seen at 60 min rather than at 20 min (P=not significant). Peak serum TSH concentrations after TRH were significantly correlated with basal values (r=(H~S, P«H)(J\, Fig. 2 ). The increment in serum TSH concentrations was also correlated with basal values (r=O·67, P«).(I02). No correlation was noted within any of the groups between serum TSH and IT 4 • tT.J or tT 3 concentrations.
The proportion of patients requiring replacement therapy (other than thyroxine) was significantly greater in group A than in group B (7/X vs 2/12, !)<().Il\).
Discussion
The new sensitive immunometric assays for TSII offer considerable advantages over con-JRMA-TSH in pituitary disease 623 ventional radioimmunoassay (RIA). With superior precision these assays have detection limits an order of magnitude lower than RIA. whilst the use of two monoclonal antibodies directed to different sites of the TSH molecule greatly reduces the chances of cross-reactivity with other glycoprotein hormones or hormone fragments (such as luteinizing hormone or a chains). The IRMA-TSH method is thus particularly applicable to the study of patients with destructive pituitary lesions in whom low or normal serum TSH concentrations might be expected to occur.
In the patients with destructive pituitary lesions TSH was detectable by IRMA in the sera of all but one patient, but the mean level was significantly lower in those with subnormal IT4 than in the biochemically euthyroid patients. This criterion for diagnosing secondary hypothyroidism is of course arbitrary, but the tT4 and tT3 results are strikingly concordant with the IT 4 and support this classification. The group A patients also had a high prevalence of insufficiency of other pituitary hormones, indicating that they had, as a result of their lesions and the treatments applied, suffered more extensive damage to the pituitary and hypothalamus than the group B patients. In all patients TSH increased after intravenous TRH injection. As in normal subjects," a close correlation between basal TSH values and the TRH-induced peak values was observed. There is thus little diagnostic yield to be obtained from the TRH test in this circumstance, if the basal TSH can be measured with precision.
A delayed rise in serum TSH in response to TRH (with the 60 min being greater than the 20 min value) is widely believed to be helpful in the differential diagnosis of secondary hypothyroidism.f () being characteristic of hypothalamic rather than pituitary involvement. However. a delayed response may also be seen in patients with primary pituitary disease": II and is in practice of little use in distinguishing pituitary from hypothalamic disease. The degree of TSH responsiveness to intravenous TRH is moreover influenced by changes in other hormones, particularly growth hormone and cortisol,":" making the interpretation of this test difficult in individual patients with pituitary disorders. All our patients with low IT4 were also receiving hydrocortisone replacement therapy which could have influenced the TSH results we obtained. However in physiological replacement dosage such therapy does not suppress TSH signifi-cantlyZ nor could it account for the low circulating thyroid hormone levels in these patients. Moreover. growth hormone deficiency. which was documented in some of the group A patients. would tend to elevate serum TSH and offset such an effect. II Although mean serum TSH concentrations were significantly lower in the group A than in group Band C subjects. basal TSH values in three of the eight group A patients were within the range seen in our control subjects. and were thus theoretically of an order sufficient to maintain normal thyroxine production. This has been noted in many studies and there are several possible explanations. Firstly. there may have been coincident primary thyroid disease. but we have excluded this in our patients as far as possible. Secondly. disruption of the hypothalamic-pituitary axis could impair feedback so that serum TSH is inappropriately low for the prevailing serum thyroxine concentration. Thirdly. TSH of reduced bioactivity may be produced': [12] [13] [14] if the hypothalamus is disrupted. Finally. it is possible that disturbance of the fattern of pulsatile or diurnal TSII release I • 16 could also impair the responsiveness of the thyroid to TSH.
It is clear that a variety of mechanisms can result in hypothyroidism secondary to destructive pituitary lesions. Our studies using a sensitive TSH assay indicate that simple thyrotroph destruction is likely to be one of these mechanisms. Since the serum TSH concentrations may be subnormal. normal or raised in secondary hypothyroidism. it is evident that the biochemical diagnosis of this condition must still rest upon measurement of free and/or total thyroid hormone concentrations. The clinical utility of the TRH test in assessing the putative site of the functional lesion or the need for thyroxine replacement is doubtful.
